Why is petrelintide interesting if it produces less weight loss than retatrutide?

Because the bet is on tolerability rather than peak efficacy. In phase 2 it reported no vomiting and no gastrointestinal discontinuations at the maximally effective dose, against roughly 11% discontinuation at retatrutide's top phase 3 dose. A drug people can stay on for years may outperform a stronger drug that a meaningful fraction of users abandon.

Is petrelintide available anywhere?

No. It is an investigational compound developed by Zealand Pharma in partnership with Roche, and it is not approved for human use in any country. Phase 2 ZUPREME-1 reported in 2026, with ZUPREME-2 in people with type 2 diabetes expected to report in the second half of 2026.

← All peptides

Weight & Metabolic

Clinical

Petrelintide

Also known as: Petrelintide

Petrelintide is a long-acting amylin analog in phase 2/3 development for weight management, notable for producing meaningful weight loss with markedly less gastrointestinal burden than incretin-based drugs.

Mechanism of Action

Petrelintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts at amylin and calcitonin receptor complexes in the hindbrain to promote satiation (the sense of having finished a meal), slow gastric emptying, and suppress post-prandial glucagon secretion. This is a distinct pathway from GLP-1 receptor agonism, which is why the tolerability profile differs so sharply. The molecule was engineered for chemical and physical stability without fibrillation near neutral pH, which permits co-formulation and co-administration with other peptides — a deliberate design choice supporting future combination products.

Half-life: Designed for once-weekly subcutaneous administration; exact half-life not publicly characterized
Administration Routes: subcutaneous
Research Status: Clinical